Clinical Trial Update: Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial TEDDI-R evaluating a combination of temozolomide, etoposide, liposomal doxorubicin (Doxil), dexamethasone, ibrutinib, and rituximab for a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Decadron (Dexamethasone)
• Doxil (liposomal doxorubicin)
• IMBRUVICA (IBRUTINIB)
• Rituxan (rituximab)
• Temodar (Temozolomide)
• Toposar (Etoposide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING